Trial · NCT02278796

A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)

NCT02278796, Phase 2, Completed, Insel Gruppe AG, University Hospital Bern; results first posted 2025-08-01

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial). Trials, record NCT02278796. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02278796

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)
NCT number: NCT02278796
Status: Completed
Phases: Phase 2
Enrollment: 108 participants, actual
Lead sponsor: Insel Gruppe AG, University Hospital Bern
Conditions: Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell
Interventions: BeEAM, BEAM
First posted: 2014-10-30
Last updated: 2025-08-01
Other registries' IDs: eudract:2014-003629-16
Results first posted: 2025-08-01

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Patients With a Clinically Meaningful Reduction in Lung Toxicity, Defined as a Reduction of the Diffusion Capacity of the Lung for Carbon Monoxide (DLCO) by at Least 20%.	100 days	Number of patients with a clinically meaningful reduction in lung toxicity, defined as a reduction of the diffusion capacity of the lung for carbon monoxide (DLCO) by at least 20%. DLCO measured in mmol/min/kPA
Secondary	Acute Toxicity/Adverse Events (CTCAE4)	≤ 35 days	Overall number of adverse events grade 3-5 at ≤ 35 days after ASCT (CTCAE4)
Secondary	Hematologic Recovery and Engraftment (ANC)	100 days	Hematologic recovery measured as median time (days) to ANC \>0.5 × 10 \^9/l
Secondary	Percentage of Patients With Overall Survival	1 year	Percentage of patients alive after autologous stem cell transplantation after one year
Secondary	Late Toxicity/Adverse Events (CTCAE4)	Continuously up to 1 year	Number of events grade 3-5 AE at 1 year after ASCT (CTCAE4)
Secondary	Hematologic Recovery and Engraftment (PLT)	100 days	Hematologic recovery neasured as median time (days) to PLT \>20 × 10\^9/l

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Number of Patients With a Clinically Meaningful Reduction in Lung Toxicity, Defined as a Reduction of the Diffusion Capacity of the Lung for Carbon Monoxide (DLCO) by at Least 20%.	100 days	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Acute Toxicity/Adverse Events (CTCAE4)	≤ 35 days	Events	NUMBER
SECONDARY	Hematologic Recovery and Engraftment (ANC)	100 days	days	MEDIAN
SECONDARY	Percentage of Patients With Overall Survival	1 year	percentage of participants	NUMBER
SECONDARY	Late Toxicity/Adverse Events (CTCAE4)	Continuously up to 1 year	events	NUMBER
SECONDARY	Hematologic Recovery and Engraftment (PLT)	100 days	days	MEDIAN

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Number of Patients With a Clinically Meaningful Reduction in Lung Toxicity, Defined as a Reduction of the Diffusion Capacity of the Lung for Carbon Monoxide (DLCO) by at Least 20%.	BeEAM	8		Participants
Number of Patients With a Clinically Meaningful Reduction in Lung Toxicity, Defined as a Reduction of the Diffusion Capacity of the Lung for Carbon Monoxide (DLCO) by at Least 20%.	BEAM	11		Participants
Acute Toxicity/Adverse Events (CTCAE4)	BeEAM	19		Events
Acute Toxicity/Adverse Events (CTCAE4)	BEAM	17		Events
Hematologic Recovery and Engraftment (ANC)	BeEAM	10	Inter-Quartile Range 10 to 11	days
Hematologic Recovery and Engraftment (ANC)	BEAM	10	Inter-Quartile Range 10 to 11	days
Percentage of Patients With Overall Survival	BeEAM	92.3	95% Confidence Interval 80.8 to 97	percentage of participants
Percentage of Patients With Overall Survival	BEAM	88.6	95% Confidence Interval 76.3 to 94.7	percentage of participants
Late Toxicity/Adverse Events (CTCAE4)	BeEAM	22		events
Late Toxicity/Adverse Events (CTCAE4)	BEAM	6		events

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	BeEAM	53
Overall Study	STARTED	BEAM	55
Overall Study	COMPLETED	BeEAM	51
Overall Study	COMPLETED	BEAM	52
Overall Study	NOT COMPLETED	BeEAM	2
Overall Study	NOT COMPLETED	BEAM	3

Source ClinicalTrials.gov

Adverse events4

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Gastrointestinal disorders	Gastrointestinal disorders	BeEAM	31	53	31
other	Gastrointestinal disorders	Gastrointestinal disorders	BEAM	25	55	25
serious	Infection	Infections and infestations	BeEAM	6	53	6
serious	Infection	Infections and infestations	BEAM	6	55	6

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	BeEAM	4	53
Total, all-cause mortality	BEAM	6	55
Total, other adverse events	BeEAM	31	53
Total, other adverse events	BEAM	25	55
Total, serious adverse events	BeEAM	6	53
Total, serious adverse events	BEAM	6	55

Source ClinicalTrials.gov

Papers6

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
7477169	RESULT	PubMed
10673703	RESULT	PubMed
21816830	RESULT	PubMed
23749106	RESULT	PubMed
24591201	RESULT	PubMed
38024477	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
BeEAM vs BEAM: Number of Patients With a Clinically Meaningful Reduction in Lung Toxicity, Defined as a Reduction of the Diffusion Capacity of the Lung for Carbon Monoxide (DLCO) by at Least 20%.	Trial comparisons
BeEAM vs BEAM: deaths from any cause	Trial comparisons
BeEAM vs BEAM: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02278796

GET https://conductscience.org/api/trials/v1/NCT02278796/registered

API reference For AI assistants